Stockscreener 앱 받기
33.17
0.70%
-0.2425
Supernus Pharmaceuticals Inc 주식(SUPN)의 최신 뉴스
Supernus Pharmaceuticals Announces Expiration of - GlobeNewswire
What are the latest earnings results for Supernus Pharmaceuticals Inc.Capitalize on emerging investment opportunities - jammulinksnews.com
Supernus announces expiration of HSR waiting period for Sage Therapeutics - TipRanks
Supernus-Sage acquisition clears antitrust hurdle as HSR waiting period expires - Investing.com Australia
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - Benzinga
Supernus-Sage $12B Merger Gets Key Regulatory Green Light as Tender Offer Deadline Nears - Stock Titan
Is Supernus Pharmaceuticals Inc. a growth stock or a value stockMaximize portfolio growth with strategic plans - jammulinksnews.com
How many analysts rate Supernus Pharmaceuticals Inc. as a “Buy”Free Risk Assessment Services - jammulinksnews.com
What is the dividend policy of Supernus Pharmaceuticals Inc. stockMaximize gains with proven stock analysis - jammulinksnews.com
What are the technical indicators suggesting about Supernus Pharmaceuticals Inc.Unlock powerful market analysis and alerts - jammulinksnews.com
Why is Supernus Pharmaceuticals Inc. stock attracting strong analyst attentionAccess exclusive market insights for free - jammulinksnews.com
Can Mixed Fundamentals Have A Negative Impact on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Current Share Price Momentum? - 富途牛牛
What institutions are buying Supernus Pharmaceuticals Inc. stock nowBreakthrough stock performance - jammulinksnews.com
What drives Supernus Pharmaceuticals Inc. stock priceDouble or triple returns - PrintWeekIndia
What analysts say about Supernus Pharmaceuticals Inc. stockRapid wealth creation - Autocar Professional
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) - FinancialContent
What makes Supernus Pharmaceuticals Inc. stock attractive to long term investorsBreakout portfolio performance - jammulinksnews.com
Supremex Announces Date of Its 2025 Second Quarter Results Conference Call - Yahoo.co
Is Supernus Pharmaceuticals Inc. a good long term investmentExtraordinary performance - Autocar Professional
Supernus Pharmaceuticals Inc. Stock Analysis and ForecastStrong return on investment - Autocar Professional
Benign Growth For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Underpins Its Share Price - simplywall.st
Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Hold" at Wall Street Zen - MarketBeat
Published on: 2025-07-23 12:28:32 - Autocar Professional
Supernus Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 5 - Nasdaq
Supernus Pharmaceuticals to Announce Second Quarter 2025 - GlobeNewswire
SUPN SEC FilingsSupernus Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
CNS Drug Leader Supernus Pharmaceuticals Sets Q2 2025 Earnings Call with CEO Presentation - Stock Titan
Supernus Pharmaceuticals Faces 3.2% Share Decline: Sector Challenges ImpactNews and Statistics - IndexBox
(SUPN) Investment Report - news.stocktradersdaily.com
Why Supernus Pharmaceuticals (SUPN) Shares Are Falling Today - Yahoo Finance
Is Supernus Pharmaceuticals Inc. stock a growth or value playQuick Profit Idea Stream - Newser
0.37%
0.48%
자본화:
|
볼륨(24시간):